[Human papillomavirus vaccine. Efficacy and safety].
Human papillomavirus (HPV) related disease remains a major cause of morbidity and mortality worldwide. Prophylactic vaccines have been recognized as the most effective intervention to control for HPV-related diseases. This article reviews the major phaseii/iii trials of the bivalent (HPVs16/18), quadrivalent (HPVs6/11/16/18), and the recently approved 9-valent vaccine (HPVs6/11/16/18/31/33/45/52/58). Large trials have been conducted showing the safety, immunogenicity and high efficacy of the bivalent and quadrivalent vaccines in the prevention of pre-invasive lesions and infection, especially when administered at young ages before exposure to HPV. Trials of the 9-valent vaccine have also demonstrated the safety, immunogenicity and efficacy of the vaccine in the prevention of infection and disease associated with the vaccine types, and its potential to substantially increase the overall prevention of HPV-related diseases. Post-licensure country reports have shown the recent and early impact of these vaccines at population level after the implementation of established HPV vaccination programs, including decreases in the prevalence of vaccine HPV types, the incidence of genital warts, and the incidence of high-grade cervical abnormalities. If widely implemented, current HPV vaccines may drastically reduce the incidence of cervical cancer and other HPV-related cancers and diseases.
Programa de Investigación en Epidemiología del Cáncer, Unidad de Infecciones y Cáncer (UNIC), Institut Català d'Oncologia (ICO) - IDIBELL, L'Hospitalet de Llobregat, Barcelona, España; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, España.
Laia
L
Bruni
Programa de Investigación en Epidemiología del Cáncer, Unidad de Infecciones y Cáncer (UNIC), Institut Català d'Oncologia (ICO) - IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
Beatriz
B
Serrano
Programa de Investigación en Epidemiología del Cáncer, Unidad de Infecciones y Cáncer (UNIC), Institut Català d'Oncologia (ICO) - IDIBELL, L'Hospitalet de Llobregat, Barcelona, España.
Xavier
X
Bosch
Programa de Investigación en Epidemiología del Cáncer, Unidad de Infecciones y Cáncer (UNIC), Institut Català d'Oncologia (ICO) - IDIBELL, L'Hospitalet de Llobregat, Barcelona, España; CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, España. Electronic address: xcastellsague@iconcologia.net.
Xavier
X
Castellsagué
D000293:Adolescent; D000328:Adult; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000009:adverse effects / Q000276:immunology; D016896:Treatment Outcome; D055815:Young Adult
D053918:Papillomavirus Vaccines
Efficacy; Eficacia; Human papillomavirus vaccines; Safety; Seguridad; Vacunas frente al virus del papiloma humano